Legend Biotech Corporation (NASDAQ:PLRX) – Research analysts at Piper Sandler issued their Q2 2020 earnings per share estimates for Legend Biotech in a report released on Monday, June 29th. Piper Sandler analyst T. Van. Buren anticipates that the company will earn ($1.05) per share for the quarter. Piper Sandler has a “Overweight” rating and a $50.00 price objective on the stock. Piper Sandler also issued estimates for Legend Biotech’s Q3 2020 earnings at ($0.70) EPS, Q4 2020 earnings at ($1.55) EPS, FY2020 earnings at ($3.30) EPS, Q1 2021 earnings at ($0.50) EPS, Q2 2021 earnings at ($0.55) EPS, Q3 2021 earnings at ($0.60) EPS, Q4 2021 earnings at ($0.60) EPS and FY2021 earnings at ($2.25) EPS.
A number of other research analysts have also issued reports on the stock. Cowen assumed coverage on shares of Legend Biotech in a research report on Monday. They set an “outperform” rating on the stock. Needham & Company LLC assumed coverage on shares of Legend Biotech in a report on Monday. They set a “buy” rating and a $40.00 price target for the company. Finally, Citigroup assumed coverage on shares of Legend Biotech in a report on Monday. They set a “buy” rating and a $40.00 price target for the company.
Legend Biotech Company Profile
Pliant Therapeutics, Inc, a biotechnology company, discovers, develops, and commercializes treatments for fibrotic diseases. The company focuses on tissue-specific integrin modulation and EMT inhibition fibrosis diseases in lungs, liver, muscle, kidney, skin, heart, and the gastrointestinal tract. Its pipeline includes PLN-74809, an inhibitor of aVß1/aVß6 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; and PLN-1474, an inhibitor of TGF-ß activation by the integrin aVß1 for the treatment of end-stage liver fibrosis in NASH.
See Also: What is Cost of Capital?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.